Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001584774 | SCV001813660 | uncertain significance | not provided | 2019-02-01 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 30025130) |
Labcorp Genetics |
RCV001584774 | SCV002317957 | uncertain significance | not provided | 2024-12-27 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 152 of the RP1L1 protein (p.Arg152Gln). This variant is present in population databases (rs200213603, gnomAD 0.06%). This missense change has been observed in individual(s) with retinitis pigmentosa (PMID: 30025130). ClinVar contains an entry for this variant (Variation ID: 1211909). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt RP1L1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002476889 | SCV002780668 | uncertain significance | Occult macular dystrophy; Retinitis pigmentosa 88 | 2022-03-08 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001584774 | SCV003811874 | uncertain significance | not provided | 2020-08-24 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV004815574 | SCV005072223 | uncertain significance | Retinal dystrophy | 2023-01-01 | criteria provided, single submitter | clinical testing |